NEW YORK (GenomeWeb News) – Helicos Biosciences reported after the close of the market Monday that its first quarter revenues fell 53 percent as the firm continues to seek additional funds to keep its operations afloat.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.
A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.
Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.